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Abstract 25 
High quality placebo-controlled evidence for food, nutrient or dietary advice interventions is 26 
vital for verifying the role of diet in optimising health or for the management of disease. This 27 
could be argued to be especially important where the benefits of dietary intervention are 28 
coupled with potential risks such as compromising nutrient intake, particularly in the case of 29 
exclusion diets. The objective of this paper is to explore the challenges associated with 30 
clinical trials in dietary research, review the types of controls used and present the advantages 31 
and disadvantages of each, including issues regarding placebos and blinding. Placebo-32 
controlled trials in nutrient interventions are relatively straightforward, as in general placebos 33 
can be easily produced. However, the challenges associated with conducting placebo-34 
controlled food interventions and dietary advice interventions are protean, and this has led to 35 
a paucity of placebo-controlled food and dietary advice trials compared with drug trials. This 36 
review appraises the types of controls used in dietary intervention trials and provides 37 
recommendations and nine essential criteria for the design and development of sham diets for 38 
use in studies evaluating the effect of dietary advice, along with practical guidance regarding 39 
their evaluation. The rationale for these criteria predominantly relate to avoiding altering the 40 
outcome of interest in those delivered the sham intervention in these types of studies, whilst 41 
not compromising blinding. 42 
 43 
 44 
  45 
  
The challenge of control groups in dietary research 46 
Diet can impart favourable effects on health and disease risk, and can be used in the 47 
management of disease. Rigorous research design and methodology is essential in informing 48 
the precise influence of diet in each of these realms. The gold standard method for 49 
investigating the effectiveness of a therapeutic intervention (for example, drug, nutrient, food, 50 
dietary advice) is the randomised, double-blind, placebo-controlled trial (RCT). The design 51 
and conduct of drug trials is closely regulated by national and international bodies such as the 52 
Medicines and Healthcare products Regulatory Agency, the Food and Drug Administration 53 
and the European Medicines Agency. In contrast, guidelines on conducting clinical trials of 54 
dietary interventions (i.e. food or nutrient intervention, or dietary advice) do not exist.  55 
 56 
Use of placebo controls is relatively straightforward in drug and nutrient trials as products 57 
(e.g. capsules, liquids or powders) can be developed that mimic the drug or nutrient without 58 
containing the active ingredient. However, placebo design presents a major obstacle in food 59 
or dietary advice trials, and this has contributed to a paucity of placebo-controlled trials 60 
investigating the effect of dietary interventions in healthcare. This review evaluates the types 61 
of controls used in dietary trials and presents the advantages and disadvantages of each using 62 
examples from the literature. Other relevant issues such as blinding, adherence and biases 63 
will also be discussed. An example of the development of a novel placebo (sham) diet for use 64 
in an IBS trial is provided, that has until now not been detailed and will prove beneficial for 65 
future placebo-controlled dietary advice intervention trials. A glossary of terms is provided in 66 
Table 1. 67 
 68 
Controls, placebo and blinding in dietary research 69 
Benchmarking the physiological and clinical effects of an intervention group against a control 70 
group is essential for providing unambiguous evidence that the intervention is superior to not 71 
having the intervention. The effects of a drug, nutrient, food or dietary advice can be 72 
explained by its pharmacological, toxicological and/or nutritional properties. In addition, the 73 
effects can also occur due to the interaction between the individual, the prescriber (or the 74 
researcher) and the drug, nutrient, food or dietary advice creating the placebo response (2). In 75 
addition to these, food interventions or dietary advice can exert placebo effects that are 76 
influenced by previous exposure, expectation and response to particular foods, personal and 77 
cultural beliefs regarding food and diet, sensory satisfaction, taste preferences and the support 78 
and reassurance of the dietitian or nutritionist providing the advice. The response to a food 79 
  
intervention or dietary advice is therefore the sum of its impact on nutritional 80 
physiology/biochemistry and the complex factors impacting the placebo response (3), further 81 
highlighting the importance of placebo control in trials of these interventions. Bearing this in 82 
mind, there are a number of possibilities when considering the use of controls in dietary 83 
intervention studies. 84 
 85 
Uncontrolled trials 86 
Uncontrolled trials of food or dietary advice evaluate the effect of an intervention without a 87 
control group, and conclusions are based on the paired changes that occur within the 88 
intervention group only.  Although uncontrolled trials fall outside the recommendations by 89 
The International Conference on Harmonization guidelines (4), it has been estimated that one 90 
third of all clinical trials are uncontrolled (5). This approach is subject to limitations based 91 
upon the lack of opportunity to compare against a group not receiving the intervention. 92 
Therefore, it is impossible to exclude that any changes occurring over the duration of the 93 
intervention would not have occurred had the intervention not taken place, although inter-94 
subject variation is controlled for when undertaking paired comparisons.  95 
 96 
Despite these limitations, uncontrolled trials are generally easy and cheap to conduct and are 97 
appropriate for the evaluation of novel, untested, dietary interventions. They are therefore 98 
useful for exploratory studies that inform the design of larger controlled studies. Uncontrolled 99 
trials may be appropriate in patient groups in whom there are ethical risks of not providing an 100 
intervention, such as those at nutritional risk e.g. oncology (6), paediatrics (7) or in diseases 101 
with rapid or fatal progression (5). Uncontrolled trials may also be appropriate in extremely 102 
rare conditions where a sufficient sample size for both an intervention group and a control 103 
group is impossible. Therefore, although uncontrolled trials are a source of only very weak 104 
clinical evidence (5), they may be appropriate in some isolated cases. Finally, although the 105 
placebo effect is impossible to measure in uncontrolled trials, and may be particularly strong 106 
for subjective endpoints such as self-reported symptoms, it could be argued that uncontrolled 107 
trials suitably represent the effects of dietary intervention achievable in real life, as the 108 
placebo effect is commonly applied as part of many therapeutic interventions in nutrition and 109 
dietetic practice (8). 110 
 111 
Controlled trials 112 
  
There are four common types of controls utilised in intervention trials of nutrient, food or 113 
dietary advice. The following section will describe these approaches and address the 114 
advantages and disadvantages of each. 115 
 116 
No-treatment, wait list, external and historical controls 117 
The first type of control is the “no treatment” control, in which participants do not receive the 118 
intervention, nor do they receive a placebo or comparative intervention. Despite having no 119 
intervention or placebo, it is important that participants in the “no treatment” control group 120 
are evaluated using the same outcome measures at the same timepoints as those receiving the 121 
intervention to lead to a comparable Hawthorne effect between groups (the effect of 122 
measurement on response to measurement) (Table 1). Although this approach could be 123 
considered superior to the uncontrolled trial, one key issue is that participants are unblinded 124 
i.e. they have knowledge of their treatment assignment. This can result in significant 125 
expectation bias in the intervention group (i.e. the expectation of benefit could lead to more 126 
favourable outcome in those receiving treatment), which also exists in uncontrolled trials. 127 
However, there is a risk of uneven expectation bias between the “no treatment” control group 128 
(i.e. the expectation of lack of benefit could lead to less favourable outcome) and the 129 
intervention group. This may be particularly important in trials of treatments with subjective 130 
outcomes (e.g. quality of life, symptom reporting). 131 
 132 
A special type of no treatment control that is commonly used in dietary intervention studies is 133 
a wait-list control (i.e. patients waiting for a routine appointment) who present a convenient 134 
“no treatment” control population (9-11). The advantage of this is the ethical benefit of patients 135 
obtaining treatment who are seeking care. However, the disadvantage is that these patients 136 
are not randomised to this group, leading to a risk of allocation bias. Furthermore, at least 137 
according to behavioural research, the use of wait-list controls can overestimate treatment 138 
effect, as they change less than expected for individuals who are concerned about their 139 
behaviour (12). However, other evidence suggests the expectation of future intervention in 140 
wait-list controls could also lead to unwanted improvement in endpoints, essentially leading 141 
to an underestimation of effect in the treatment group. For example, wait-list controls in 142 
energy restriction studies have lost weight (10), in coeliac adherence studies they have reported 143 
improvements in quality of life (11) and in irritable bowel syndrome they have reported 144 
symptom improvements (13). Despite this, ”no treatment” controlled trials, including those 145 
utilising wait-list controls, are appropriate for trials with objective outcomes that might be 146 
  
less likely to respond to biases (e.g. the effect of a dietary intervention on blood cholesterol) 147 
and in trials where blinding is difficult (4). 148 
 149 
External or historical control groups utilise participants external to the trial. For example, in 150 
studies using hospitalised patients, historical data is collected for the external group from 151 
medical records. Of course this can potentially be limited by the level of detail that can be 152 
acquired from previously documented records. Externally or historically-controlled trials are 153 
generally also hazardous as it can never be guaranteed that the controls and the treatment 154 
group are truly sampled from the same population. Interestingly, untreated historical-control 155 
groups are reported to have worse outcomes than concurrent control groups, probably 156 
reflecting a selection bias (4). Overall, this approach is generally not recommended other than 157 
in situations where no other control group is available (4).  158 
 159 
Active comparator groups 160 
A third type of control is an active comparator group. In most instances where a dietary 161 
intervention is compared with another active intervention, the comparator group (for it is no 162 
longer an inactive control group) receives a standard treatment. For example, in a food 163 
intervention study investigating the effect of prunes on constipation, the treatment group were 164 
compared with an active comparator group in which another food is consumed, i.e. psyllium 165 
(14). In dietary advice studies, an active control might receive dietary advice that is known to 166 
have some established efficacy and is used as current best practice. For example, standard 167 
low fat dietary advice has been compared with Mediterranean dietary advice in a large 168 
multicentre trial investigating the effect of diet on cardiovascular risk (PREDIMED) (15). In 169 
Crohn’s disease, the use of whole protein enteral nutrition has been used as an active 170 
comparator when evaluating the effect of elemental enteral nutrition on achieving remission 171 
(16), and standard advice to reduce fibrous foods in active Crohn’s disease was used as an 172 
active comparator to a novel low microparticle diet (17). Standard nutritional counselling has 173 
also been compared with enteral nutrition for post-surgical patients with GI cancer (18). In 174 
irritable bowel syndrome, dietary advice considered best practice at the time has been used as 175 
an active comparator when evaluating the effect of a diet low in fermentable carbohydrates 176 
(low FODMAP diet) (19,20).  177 
 178 
Standard treatment might also consist of standard physician care, for example when 179 
evaluating the effect of dietary intervention on weight and cardiovascular disease risk factors 180 
  
(21). Whilst representing real life clinical practice, standard physician care may be limited by 181 
differing follow up frequency between groups resulting in an uneven Hawthorne effect. For 182 
example, in the study of dietitian-led team care incorporating Dietary Approaches to Stop 183 
Hypertension (DASH) advice versus standard physician care on cardiovascular risk, the 184 
active comparator group were asked to see their physician for follow up care with no other 185 
follow up throughout the six month duration of the trial (21).  186 
 187 
Trials with active comparators are used to establish the effect of a new dietary intervention as 188 
equivalent or superior to current practice (dietary or otherwise) and might be considered more 189 
ethically acceptable as all participants receive active treatment at the outset. This is 190 
particularly relevant in trials of patients with serious morbidity (22). Interestingly, physicians 191 
are more likely to recommend participant involvement in, and are more likely to prescribe 192 
drugs tested in, trials with active comparators than placebo-controlled trials (23), and patients 193 
prefer involvement in active comparator trials than placebo-controlled trials when evaluating 194 
drug efficacy (24); whether this is also true for dietary trials is unknown.  195 
 196 
One problem with an active comparator trial is the difficulty of applying homogenous advice 197 
across all the participants in the comparator group, particularly those that utilise standard 198 
care. For example, advice to implement a high fibre diet in the active comparator group will 199 
likely vary from patient to patient according to habitual fibre intake and dietary preference. 200 
This is also commonly the case when patients in an active comparator group receive standard 201 
medical care. Another issue that has arisen is when final evaluation reveals the composition 202 
of the intervention diet is not sufficiently different from the active comparator diet; a 203 
proposed point of weakness of the PREDIMED trial (25).  Poor adherence of participants 204 
within the active comparator group can also be a challenge.  205 
 206 
Blinding the active comparator diet can be difficult, which leads to a risk of uneven 207 
expectancy distribution and reduces internal validity of the trial. This may be particularly so 208 
where the active comparator is ‘standard advice’ that has been commonplace in clinical 209 
practice for some time (e.g. low fat dietary advice for cardiovascular disease). Previous 210 
exposure to ‘standard advice’ should be considered as an exclusion criterion in these 211 
situations to help minimise unblinding.  212 
 213 
Placebo controls 214 
  
The fourth and final example of a control is the placebo control. This is a "dummy" or inert 215 
treatment that appears as identical as possible to the intervention of interest. For example, in a 216 
food intervention study investigating the bone protective effect of dried plums, these were 217 
compared with a placebo control group which was allocated a different food with no bone 218 
protective properties, i.e. apple (26). The placebo-controlled trial is considered the most robust 219 
of clinical trials. Randomisation and double blinding enable minimisation of subject bias and 220 
observer bias (27). Where disease risk factors or disease endpoints are of interest, placebo 221 
controls also specifically help to account for natural progression of disease that would occur 222 
had the intervention not been prescribed (27). This type of control is generally easily 223 
accomplished in drug trials as well as in nutrient or nutraceutical supplementation studies. 224 
For example trials evaluating prebiotics (28, 29) or specific nutrients (30,31) can incorporate a 225 
placebo control in the form of a capsule or sachet produced to replicate the intervention in 226 
appearance and taste.  227 
 228 
Conducting placebo-controlled trials in food interventions or dietary advice interventions is, 229 
however, significantly more challenging. For example, there is a multitude of studies that 230 
investigate the effect of whole diet alterations (i.e. multiple contemporaneous alterations to 231 
the diet) on disease endpoints such as Mediterranean diet for improving cardiovascular 232 
health, the Atkins diet and Nordic diet for modulating weight, or the low FODMAP diet for 233 
managing symptoms of irritable bowel syndrome. However, placebo-controlled trials of 234 
whole diets are extremely rare largely because of the difficulties firstly of using a placebo 235 
control that does not significantly alter the outcome of interest and secondly of maintaining 236 
blinding.  237 
 238 
There are two methods by which a successful placebo control can be applied in studies of 239 
whole diet alteration trials. Firstly, feeding studies can be undertaken that administer all food 240 
and fluid to participants in the trial. The placebo control in feeding studies can be created 241 
bespoke for the purposes of the trial. It is developed to be ‘inert’ in nature, and is nutritionally 242 
matched in all aspects except for the active component being investigated (32). There is, 243 
therefore, a lower risk of controls experiencing improvements in the outcome of interest (e.g. 244 
plasma cholesterol or IBS symptoms) compared with active comparator trials. Furthermore, 245 
placebo controls in feeding studies can be created to be almost indistinguishable to the 246 
intervention. For example, in a placebo-controlled crossover feeding study that evaluated 247 
gluten-free, casein-free diets in autism, most parents of children could not distinguish the 248 
  
placebo diet from the experimental diet (33). In this feeding study, all meals and snacks were 249 
prepared and provided to patients for 12 weeks, and diets were individually adapted based on 250 
food preferences. With extreme effort both the patient and the investigator can be blinded to 251 
both diets. However, feeding studies are burdensome for the researcher in terms of time and 252 
economic costs and are therefore often short-term (e.g. <1 week). These factors, in addition to 253 
the artificial nature of total food provision, means that feeding studies have limited external 254 
validity as in routine clinical practice patients are not fed a therapeutic diet in a controlled 255 
environment.  256 
 257 
Secondly, it is possible to conduct placebo controlled studies of whole diet alterations using 258 
dietary advice. Dietary advice studies have the advantage over feeding studies of being 259 
representative of what is achievable in ‘real life’ settings. Typical difficulties encountered in 260 
everyday practice, such as non-adherence (34,35) and the potential for information to be 261 
misconstrued on transmission from practitioner to the patient, are replicated in these types of 262 
trials. As well as generally being less burdensome in terms of cost and time these types of 263 
trials could be argued to have greater clinical validity than feeding studies.  264 
 265 
A placebo control can be incorporated into dietary advice studies by using a re-266 
supplementation control, where the same dietary advice is given to participants in both the 267 
intervention and control groups, followed by re-supplementation of the excluded food 268 
component to the placebo group. One study has taken advantage of this study design in order 269 
to investigate the impact of the low FODMAP diet on symptoms and immune function (36). 270 
Following a low FODMAP diet run-in period for all patients, the placebo group received 271 
fructan supplementation in order to increase FODMAP intake back to habitual levels whilst 272 
the treatment group received placebo sachets (and thus were on a low FODMAP diet). A 273 
similar design was applied in a study investigating the effect of gluten supplementation on 274 
gastrointestinal symptoms and fatigue in participants with self-reported gluten intolerance. 275 
After a 2-week run-in period of a gluten free diet, the placebo group received gluten in order 276 
to normalise gluten intake, whereas the treatment group received placebo (and thus were on a 277 
gluten free diet) (37). These types of re-supplementation studies present a novel way of 278 
incorporating a placebo control in the evaluation of a dietary advice intervention. Re-279 
supplementation studies are only possible if the dietary components of interest are available 280 
in supplemental form, and it assumes the components exert the same biological effects when 281 
supplemented compared with when consumed in the diet. 282 
  
 283 
Alternatively, dietary advice trials can be placebo-controlled with the application of sham 284 
dietary advice. In this case, dietary advice is provided that is formulated to modify food 285 
intake without altering intake of nutrients or the specific food component being investigated. 286 
There is a paucity of research studies utilising sham diets, probably because of the difficulties 287 
of formulating and administering such a diet.  288 
 289 
There are at least seven sham-controlled dietary advice RCTs investigating the effect of 290 
whole diet interventions reported in the literature (Table 2) (38-45). Most evaluate the effect of 291 
an exclusion diet in gastrointestinal conditions, are of considerable size and are up to 16 292 
weeks in duration, a length of time which broadly reflects clinical practice. The rationale for 293 
the choice of foods included in the sham diet in these studies is based on self-reported 294 
tolerance (40), the patient’s usual diet (41), is relatively arbitrary (38,39,42,43) or excludes another 295 
dietary component (44). For example, one study in patients with Crohn’s disease reduced 296 
microparticle intake (inorganic calcium, food additives titanium dioxide and silicates) and 297 
compared it with a group that were provided sham dietary advice that included avoidance of 298 
the food additives sulphates and sulphur dioxide (44).  299 
 300 
Overall, very little information is provided on the design of the sham diet, and nutrient intake 301 
is not routinely measured to confirm its equivalence to the treatment. This is imperative in 302 
dietary studies where multiple dietary factors have potential to impact on endpoints (e.g. 303 
carbohydrate, protein and fat in cardiovascular disease) (46,47). Although collinearity is almost 304 
inevitable in dietary studies (e.g. altering intake of carbohydrate will lead to a change in the 305 
intake of other nutrients), confirmation that there is a clear difference in intake of the dietary 306 
component of interest between the sham diet and intervention diet is vital. There is a 307 
recommendation that the number of foods removed in a sham exclusion diet be comparable to 308 
the intervention diet (3), however detailed guidance for development and implementation of 309 
sham diets is scarce.  310 
 311 
Design and development of a sham diet for use in a placebo-controlled low FODMAP 312 
dietary advice trial  313 
Here, the design and development of the first ever sham diet for use in a low FODMAP 314 
dietary advice RCT is reported, in order to illustrate how the challenges described can be 315 
overcome, and to provide practical recommendation for sham diet development in other 316 
  
settings. The low FODMAP diet is an exclusion diet which has demonstrated effectiveness in 317 
reducing symptoms such as abdominal pain and bloating in irritable bowel syndrome (48, 49). It 318 
requires restriction of a number of short-chain carbohydrates that are ubiquitous throughout 319 
the human diet, and a majority of evidence of its effectiveness is based on dietitian-led 320 
dietary advice provided to participants. 321 
 322 
A number of criteria for the sham diet were developed in order to ensure its integrity as a 323 
placebo control for the low FODMAP diet. These criteria were developed as approach to 324 
interpreting fundamental principles in the use of placebos (their similar presentation as the 325 
intervention to facilitate blinding, physiologically inert with regards to the outcome of 326 
interest), but specifically tailored to dietary intervention studies (Table 3). These criteria in 327 
specific relation to the trial of the low FODMAP diet are: 1) to be a convincing exclusion diet 328 
in order to encourage blinding that it is actually a placebo, 2) to contain a similar number of 329 
specialist new products as the intervention diet, 3) to restrict an equivalent number of foods 330 
compared with the low FODMAP diet, 4) to take the same amount of time for shopping and 331 
involve the same level of adaptation when preparing meals as the intervention, 5) to take the 332 
same amount of time and comprehension to teach as the intervention diet, 6) to be feasible to 333 
follow, 7) to modify dietary carbohydrate sources (for ethical purposes patients were 334 
informed that the unnamed active intervention diet involved altering carbohydrate intake), 335 
and 8) to alter dietary intake but maintain FODMAP intake and 9) to not alter fibre intake, 336 
which may impact on symptoms (50). These criteria have been modified for application across 337 
all types of dietary advice trials and although these generic criteria for design of a sham diet 338 
have not been validated in trials, they provide practical approaches to facilitate blinding and 339 
limit the physiological impact of the sham diet (Table 3). 340 
The sham diet was designed following a systematic selection of foods to be included (suitable 341 
foods) and excluded (unsuitable foods). Suitable and unsuitable food lists for the low 342 
FODMAP diet were used as a starting point for creation of suitable and unsuitable food lists 343 
for the sham diet, in order to create some restriction (criterion 3), whilst neither increasing 344 
nor decreasing fructan (criterion 8) or fibre intake (criterion 9). Considering that many 345 
exclusion diets alter grain intake, some grains were restricted to give the impression that the 346 
sham diet was a true exclusion diet (criterion 1), to increase the burden of teaching (criterion 347 
5) and following the sham diet (criterion 4), to focus the sham diet on carbohydrate intake (as 348 
does the low FODMAP diet), which was referred to in the patient information sheet (criterion 349 
  
7), and to necessitate the inclusion of new food products in the diet (criterion 2). Some 350 
regularly-consumed high FODMAP foods were allocated to the suitable list in order to 351 
maintain FODMAP intake during the sham diet (criterion 8). For example, approximately 352 
half of the fruits and vegetables considered suitable on the low FODMAP diet were assigned 353 
to the unsuitable list on the sham diet, and vice versa (criterion 3), whilst dairy products were 354 
allocated to the suitable list, to ensure lactose intake was maintained on the sham diet 355 
(criterion 8). Next, the habitual diet of individuals with IBS was examined from a previous 356 
study (13) and the top 10% of foods contributing to energy and carbohydrate intake were 357 
allocated as being suitable on the sham diet in order to promote feasibility (criterion 6) and 358 
maintenance of nutrient intake (criteria 8,9). Finally, the number of unsuitable foods on the 359 
sham diet was confirmed as being approximately equivalent to that of the low FODMAP diet 360 
(criterion 3). 361 
 362 
Implementing and evaluating a sham diet 363 
Dietary counselling in sham-controlled trials should be equivalent in duration for all 364 
participants, and ideally counselling should be provided to all participants by the same 365 
researcher. Access to written dietary resources has been associated with greater likelihood of 366 
response to lifestyle interventions (51). Therefore if this type of information is to be provided, 367 
both intervention and sham diet groups should receive a similar level of written support i.e. 368 
the general format and length of the resources should be identical (criterion 5).  369 
 370 
The evaluation of a sham diet should include assessment of its achievement of the criteria 371 
described in Table 3, and this can be achieved in a variety of ways. One approach is to 372 
undertake a pilot study whereby participants are advised to follow the sham diet and 373 
undertake a dietary assessment at baseline (habitual diet) and during the sham diet (criteria 374 
8,9). An acceptability questionnaire can evaluate feasibility and other important outcomes 375 
(criterion 4, 6), as well as assessment of blinding (criterion 1). The sham diet can also be 376 
evaluated as part of the final RCT, and this can be undertaken both during the trial (i.e. an a 377 
priori interim analysis) and at the end of the trial (i.e. final analysis). If an interim analysis of 378 
a sham diet is undertaken, it should be performed late enough so that sufficient numbers can 379 
be included in the analysis but early enough in the case that the sham diet requires alteration. 380 
If changes to the sham diet are required this may require contact with the body providing 381 
ethical approval, and alterations should be carefully recorded and reported in the subsequent 382 
publication. In regards to the final analysis, evaluation of changes in dietary intake between 383 
  
baseline and the sham diet and between sham and the intervention diet should be reported in 384 
any publication to confirm the placebo nature of the sham diet. Interim and final analyses 385 
must be conducted by an investigator who is blinded to the dietary allocation, in order to 386 
prevent researcher bias during dietary coding. Clearly, dietary assessment should use gold 387 
standard methods where possible. 388 
 389 
Conclusions  390 
High quality placebo-controlled evidence for food or dietary interventions is vital for 391 
verifying their role in optimising health or for the management of disease. This is especially 392 
important where the benefits of dietary intervention are coupled with potential safety 393 
implications such as compromising nutrient intake. The challenges with conducting placebo-394 
controlled research in dietary trials are acknowledged. Sham diets are one approach of 395 
implementing placebo controls in dietary advice trials. Any new sham diet should be 396 
rigorously designed, implemented and tested as described. Feasibility, preservation of 397 
blinding, maintaining intake of the dietary component being investigated in the treatment 398 
group are major priorities when designing a sham diet which we propose can be addressed 399 
with careful consideration of the recommendations outlined. 400 
  
Table 1: Glossary of terms relevant in dietary intervention trials  
Term Definition  
Trials  
Dietary advice trial A trial investigating the effect of dietary advice (written and/or verbal)  
Food intervention trial A trial investigating the effect of addition of a specific food into the diet 
Nutrient intervention trial A trial investigating the effect of addition of a nutrient into the diet, usually provided in the form of a supplement (e.g. capsule, 
liquid or powder) 
Placebo-controlled trial A trial incorporating a placebo control  
Randomised controlled trial A trial that randomly allocates participants to a control group or the treatment group 
Uncontrolled trial A trial that does not incorporate a control group. Paired changes between baseline and follow-up are evaluated to assess outcome.  
Controls  
Active comparator control A control group that receives an active intervention (e.g. standard therapy), usually used to determine whether the treatment under 
investigation is superior to standard therapy 
Control  A group of participants not receiving the intervention that is compared with an intervention group, which enables comparison of the 
effect of the treatment 
External control A control group outside of the trial that is used to compare with the treatment group (e.g. data from medical records). 
Feeding study control Controlled study in which all food and fluid is provided to participants and in which the placebo group receive a diet designed 
bespoke for the purposes of the trial to be ‘inert’ in nature, and nutritionally matched to the intervention diet in all aspects except 
for the active component being investigated 
No treatment control A control group that do not receive a placebo or comparative intervention  
Placebo control  A control group that receives an inert substance (e.g. sugar pill or saline) or sham advice/treatment 
Re-supplementation control Controlled study in which the same dietary advice is given to participants in both the intervention and control groups, followed by 
re-supplementation of the excluded food component to the placebo group 
Sham diet control Control whereby dietary advice is provided that modifies food intake without altering intake of nutrients or the specific food 
component being investigated 
Bias, blinding, placebo  
Allocation bias Bias resulting from a systematic difference between treatment and control groups in a trial, other than the intervention. This can 
largely be avoided by using randomisation. 
Expectation bias Bias resulting from the effect of participants’ expectation of outcome (positive or negative) 
Hawthorne effect The effect of observation and/or measurement of research participants on outcomes 
Observer bias The inadvertent influence by the observer/researcher on participants  
Placebo effect  Average improvement of a symptom or physiological condition following a placebo intervention in a RCT. The ‘true’ placebo 
effect is the effect after removing other contributing factors such as the natural course of the disease or spontaneous fluctuations 
Selection bias Selection of participants for inclusion in a research trial, or data analysis, such that it is not representative of the overall population 
Subject bias Bias resulting from participants behaving, or reporting to behave, in a way they think the researcher wants them to 
Some definitions adapted from (1) 
  
Table 2: Sham diet-controlled dietary advice RCTs 
Reference Treatment Patient 
population 
Study design/duration Sham diet Mode of advice 
(38) Exclusion diet removing foods 
based on presence of IgG 
antibodies specific to a panel 
of 113 food antigens 
Migraine 
n=167 
12-week single-blind parallel 
design RCT 
Excluded same number of foods as proposed 
treatment diet (mean number of food per patient 
excluded not reported)  
 
Foods excluded did not provoke positive IgG 
antibody response and chosen based on difficulty of 
excluding foods from the true diet 
 
Success of blinding not reported 
Verbal and written 
advice 
(39) Exclusion diet removing foods 
based on presence of IgG 
antibodies specific to a panel 
of 29 food antigens 
Irritable 
bowel 
syndrome  
n=150 
12-week double-blind parallel 
design RCT 
Excluded same number of foods as proposed 
treatment diet (mean excluded foods per patient=6). 
 
Foods excluded did not provoke positive IgG 
antibody response and chosen based on difficulty of 
excluding foods from the true diet 
 
Success of blinding not reported 
Verbal and written 
advice with access 
to a nutritional 
advisor throughout 
if required 
(40) Exclusion diet  based on foods 
well tolerated according to 
clinical experience (rice, 
potato, lamb, bean, and peas) 
Anal 
fissure 
n=161 
8-week double-blind parallel 
design RCT  
Elimination of foods reported as not tolerated by 
patients according to clinical experience (milk 
products, wheat, eggs, tomato, chocolate) 
 
Success of blinding not reported 
Not reported 
(41) Nutrient dense low energy diet Bulimia 
nervosa 
n=10 
6-9 week single-blind, parallel 
design controlled trial 
Treatment group followed 
treatment diet for 6 weeks 
Control group followed 3-week 
sham diet followed by 6-week 
treatment diet  
Based on baseline dietary preferences 
 
Success of blinding not reported 
Written advice 
(42) Exclusion diet removing foods 
based on presence of IgG 
antibodies 
Crohn’s 
disease 
n=40 
12-week double-blind parallel 
design RCT 
Excluded same number of foods as proposed 
treatment diet (mean number of food per patient 
excluded not reported).  
 
Foods excluded did not provoke positive IgG 
Written advice, 
recipes, menus and 
Access to a 
nutritional advisor 
throughout if 
  
antibody response and chosen based on difficulty of 
excluding foods from the true diet 
 
Success of blinding not reported 
required 
(43) 
abstract 
only 
Exclusion diet excluding foods 
based on presence of highest 
IgG antibody response to four 
foods  specific to a panel of 29 
food antigens 
Crohn’s 
disease 
n=98 
4-week double-blind parallel 
design RCT 
Four foods with the lowest IgG4 titres excluded 
 
Success of blinding not reported 
Written advice 
provided by a 
dietitian 
(44) Exclusion diet excluding foods 
high in microparticles 
(particulate silicates and 
titanium dioxide) 
Crohn’s 
disease 
n=83 
16-week single-blind randomised 
2x2 factorial trial 
 
Foods containing  sulphur dioxide 
and sulphites excluded 
 
Success of blinding not reported 
Verbal and written  
advice provided by 
a dietitian 
(45) 
 
Exclusion diet excluding 
selected carbohydrate foods 
(low FODMAP diet) 
Irritable 
bowel 
syndrome 
n=104 
4-week single-blind randomised 
2x2 factorial trial 
Selected fruit, vegetables, grains excluded, with 
final number of foods equivalent to treatment diet  
 
Success of blinding not reported 
Verbal and written 
advice provided by 
dietitian 
  
Table 3: Important criteria for the development of a sham diet that may improve 
blinding and maintain the placebo nature of the diet 
 Criteria Rationale 
Criterion 1 The content of the sham diet must give the impression it 
is the true intervention diet  
To facilitate blinding 
Criterion 2 If relevant, the content of the sham diet must require a 
similar number of specialist or ‘new’ foods compared 
with the intervention diet 
To equalise the difficulty of the diet 
in order to facilitate blinding  
Criterion 3 The sham diet must restrict or modify intake of an 
equivalent number of foods as the intervention diet 
To equalise difficulty of the diet in 
order to  facilitate blinding 
Criterion 4 The burden of the sham diet should be equivalent to the 
intervention diet (e.g. time for shopping and cooking, 
level of adaptation required for preparing meals) 
To equalise difficulty of the diet in 
order to  facilitate blinding  
Criterion 5 The sham diet takes the same amount of time to teach 
and requires same amount of comprehension as the 
intervention diet 
To limit investigator bias and 
facilitate blinding  
Criterion 6 The sham diet must be feasible to follow To facilitate adherence 
Criterion 7 The sham diet must modify dietary intake in a similar 
way to the intervention diet such that they can both be 
described in ethics documentation and information 
sheets without unblinding 
 
To meet ethical requirements and to 
create a convincing placebo 
Criterion 8 The sham diet must alter dietary intake but maintain 
intake of foods, food components or nutrients under 
investigation  
To limit responses in the placebo 
group 
Criterion 9 The sham diet must not alter intake of other foods, food 
components or nutrients that might impact on endpoints 
To limit responses in the placebo 
group 
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